Home Clinical Trial Updates

Clinical Trial Updates

Changing Clinical Trial Enrollment Criteria Dramatically Increases Participation of Eligible Patients...

Restrictive eligibility criteria may limit or even jeopardize data generalizability of the trial results and opportunities for patients to participate in a...

Laparoscopic Surgery vs. Open Surgery in Patients with Colorectal Cancer with...

Despite the worldwide dissemination and acceptance of laparoscopic liver surgery, the long-term oncologic outcomes of laparoscopic and open liver surgery have never...

Enfortumab Vedotin Produces a High Tumor Response Rate in Patients with...

Earlier this year, positive top-line results from the first cohort evaluating the investigational antibody-drug conjugates (ADC) enfortumab vedotin (also known as ASG-22CE) showed...

Sub-population Analysis Shows High Rates of Durable Response and Overall Survival...

Findings from two new analyses from the ZUMA-1 trial of axicabtagene ciloleucel (Yescarta®;Kite Pharma) in adult patients with relapsed or refractory large...

Phase I ZUMA-3 Results for KTE-X19 in ALL Show High Rates...

Results from the completed Phase I of the ZUMA-3 study, a single-arm, multicenter, registrational Phase I/II study evaluating KTE-X19 (Kite Pharma), an...

Prioritizing the Importance of the Immune System

Neoadjuvant use of immunotherapy, the administration of therapeutic agents before surgery, can be more effectively applied. The advantage may include a better...

Liquid Biopsy Platform Demonstrates High Diagnostic Capabilities In Early Stages of...

Commercial-stage medical technology company Laboratory for Advanced Medicine (LAM) announced positive results from a new study that evaluated DNA methylation-based marker...

Growing Importance of Community Oncologists in Clinical Research Evidenced by Large...

Investigators from McKesson, The US Oncology Network and US Oncology Research will present detailed findings from more than 60 studies during the...

New Data From ZUMA Trials Offer Greater Understanding of CAR T-cell...

New, updated data from cell therapy programs including axicabtagene ciloleucel (Yescarta®; Kite Pharma) and KTE-X19, an investigational company’s chimeric antigen...

Alpelisib Approved as the First and Only Treatment Specifically for Patients...

The U.S. Food and Drug Administration (FDA) has approved alpelisib (Piqray®; formerly BYL719), a kinase inhibitor developed by Novartis, in combination...

LATEST